Comparative effectiveness of three treatment strategies for submacular hemorrhage secondary to age-related macular degeneration

Le résumé fourni par la source

Abstract We aimed to compare the effectiveness of three treatment strategies for extensive submacular hemorrhage (SMH) secondary to age-related macular degeneration (AMD): intravitreal anti-vascular endothelial growth factor (VEGF) monotherapy, anti-VEGF combined with sulfur hexafluoride (SF₆) gas tamponade, and triple therapy consisting of anti-VEGF, SF 6 gas, and intravitreal tissue plasminogen activator (tPA). This multicenter retrospective study included 61 eyes of 61 patients treated at three institutions. Patients received anti-VEGF monotherapy (n = 19), anti-VEGF plus SF 6 gas tamponade (n = 20), or triple therapy (n = 22). Inclusion criteria were logMAR best-corrected visual acuity (BCVA) ≥ 0.40, SMH ≥ 2 disc diameters, and treatment within 14 days of onset. The primary outcome was longitudinal BCVA change over 12 months, analyzed using a linear mixed-effects model adjusted for baseline BCVA. A significant overall treatment effect was observed, with triple therapy demonstrating consistently superior BCVA. Unadjusted 12-month BCVA also differed significantly among groups. Treatment modality and baseline ellipsoid zone integrity were independent predictors of 12-month BCVA. Hematoma displacement rates were 100%, 35.0%, and 5.3%, and re-hemorrhage rates were 18.2%, 55.0%, and 42.1% in the triple, combination, and monotherapy groups, respectively. Triple therapy provided superior and more predictable visual and anatomical outcomes, supporting early intervention.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.